Evidence map›Paper›PMID 40041768›Full record

ArticleiScience2025

RGS2 is an innate immune checkpoint for suppressing Gαq-mediated IFNγ generation and lung injury.

Jagdish Chandra Joshi, Bhagwati Joshi, Cuiping Zhang, Somenath Banerjee, Vigneshwaran Vellingiri, Vijay Avin Balaji Raghunathrao, Mumtaz Anwar, Tejas Pravin Rokade, Lianghui Zhang, Ruhul Amin and 2 more

Abstract read
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Jagdish Chandra JoshiDepartment of Pharmacology and Centre for Lung and Vascular Biology, University of Illinois, College of Medicine, Chicago, IL, USA.
Bhagwati JoshiDepartment of Pharmacology and Centre for Lung and Vascular Biology, University of Illinois, College of Medicine, Chicago, IL, USA.
Cuiping ZhangDepartment of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Somenath BanerjeeDepartment of Pharmacology and Centre for Lung and Vascular Biology, University of Illinois, College of Medicine, Chicago, IL, USA.
Vigneshwaran VellingiriDepartment of Pharmacology and Centre for Lung and Vascular Biology, University of Illinois, College of Medicine, Chicago, IL, USA.
Vijay Avin Balaji RaghunathraoDepartment of Pharmacology and Centre for Lung and Vascular Biology, University of Illinois, College of Medicine, Chicago, IL, USA.
Mumtaz AnwarDepartment of Pharmacology and Centre for Lung and Vascular Biology, University of Illinois, College of Medicine, Chicago, IL, USA.
Tejas Pravin RokadeDepartment of Pharmacology and Centre for Lung and Vascular Biology, University of Illinois, College of Medicine, Chicago, IL, USA.
Lianghui ZhangDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Vascular Medicine Institute, Center for Vaccine Research, University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA.
Ruhul AminDepartment of Pharmacology and Centre for Lung and Vascular Biology, University of Illinois, College of Medicine, Chicago, IL, USA.
Yuanlin SongDepartment of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Dolly MehtaDepartment of Pharmacology and Centre for Lung and Vascular Biology, University of Illinois, College of Medicine, Chicago, IL, USA.

Funding

The Lung Endothelium as an Instructive Niche for the Innate Immune System during Vascular InjuryP01HL160469 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Jalees Rehman · 2022 to 2026
$14.0M
Synthetic Biology and Optogenetics CoreP01HL151327 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MEHTA, DOLLY · 2021 to 2025
$11.8M
Focal Adhesion Kinase Regulation of Lung Vascular Permeability and EdemagenesisR01HL084153 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MEHTA, DOLLY · 2007 to 2022
$5.4M
Targeting mechanisms activating ion-channel for preventing acute lung injuryR01HL165263 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DOLLY MEHTA · 2023 to 2026
$2.4M
CREB Instruction of Macrophage Fate and Lung fluid homeostasisR01HL155941 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MEHTA, DOLLY · 2021 to 2024
$636k
NHLBI NIH HHS P01 HL151327NHLBI NIH HHS P01 HL160469NHLBI NIH HHS R01 HL084153NHLBI NIH HHS R01 HL155941NHLBI NIH HHS R01 HL165263
6 · The paper itself

Abstract

Interferon gamma (IFNγ), a type II interferon, augments tissue inflammation following infections, leading to lethal acute lung injury (ALI), yet the mechanisms controlling IFNγ generation in the lungs remain elusive. Here, we identified regulator of G protein signaling 2 (RGS2) as a gatekeeper of the lung's IFNγ levels during infections. Deletion of RGS2 sustained an increase in IFNγ levels in macrophages, leading to unresolvable inflammatory lung injury. This response was not seen in RGS2 null chimeric mice receiving wild-type (WT) bone marrow or the RGS2 gene in alveolar macrophages (AMs) or IFNγ-blocking antibody. RGS2 functioned by suppressing Gαq-mediated IFNγ generation and AM inflammatory signaling. Thus, the inhibition of Gαq blocked IFNγ generation in AMs and rewired AM transcriptomes from an inflammatory to a reparative phenotype in RGS2 null mice, pointing to the RGS2-Gαq axis as a potential target for suppressing inflammatory injury.

Indexed as

ImmunologyMolecular biology

Identifiers

PMID40041768
PMCPMC11876898

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.